Danaher DHR

Reference table

1. What the business is, and what the vendor's segment data is not

Danaher reports three segments. The vendor payload contains none of them.

From the 10-K's Note 5, FY2025 ($M):

Three segments, three flat lines. Over two years the fastest grew 3.8% cumulatively. Masimo, acquired 10 June 2026, sits inside Diagnostics and adds roughly $1.5 billion of annual revenue to that segment — a 15% step-up in the largest segment, arriving by purchase.

The revenue-type disclosure is the quality argument and it is the best number in the file:

Recurring revenue grew 7.7% over two years while nonrecurring fell 14.7% — the signature of an instrument-and-consumables business coming out of a capital-equipment downturn with its installed base intact. Recurring revenue by segment in FY2025: Biotechnology $6,424M of $7,293M (88.1%), Diagnostics $8,859M of $9,941M (89.1%), Life Sciences $4,844M of $7,334M (66.1%).

The vendor's seg_prod block contains this recurring/nonrecurring table and calls it a product segmentation. It is labelled "Revenue from Contract with Customer, Measurement, Recurring" and "...Nonrecurring", sums correctly to revenue, and is genuinely useful — but it is not the segment table, and a reader treating it as one would conclude Danaher has two businesses. It has three, and they are absent.

Geography, from the 10-K's Note 5 (FY2025, $M):

And from the separate country table: United States $9,981M (40.6%), China $2,631M (10.7%), all other $11,956M.

The vendor's seg_geo for FY2025 contains only two lines — "Other developed markets" $11,956M and "CHINA" $2,631M — summing to $14,587M against reported revenue of $24,568M. It has taken the country table, mislabelled the "All other" line as "Other developed markets", and dropped the United States line of $9,981M entirely. The single largest geography, 40.6% of the company, is missing. The FY2024 entry is complete (it carries a "North America" line of $9,927M, which is actually the United States figure, again mislabelled). No geographic conclusion in this dive uses the vendor block; all of it comes from the 10-K.

And the vendor's profile description is two segment structures out of date. It states Danaher "is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions." Environmental & Applied Solutions was separated as Veralto in October 2023. The current third segment is Biotechnology. The same profile block names Rainer Blair as chief executive, superseded on 2026-08-03 (see Section 2).

Danaher's core-growth disclosure changed this quarter and the change is worth noting. From the second-quarter release: "Beginning with the Company's Quarterly Report on Form 10-Q for the second quarter of 2026, in addition to disclosing core sales growth, the Company is disclosing a new non-GAAP measure, titled 'Core sales growth excluding respiratory testing.'" And "beginning with the... third quarter of 2026, the Company intends to exclude from the core sales measures the impact, if any, of tariff refunds." Two new adjustment layers added to the growth metric in two consecutive quarters, both of which raise the reported number — June-quarter core growth was +3.0% total, or +4.5% excluding respiratory testing. The rationale given (respiratory demand depends on flu severity and is "not under management's control") is reasonable. We report both figures everywhere and treat the adjusted version as management's preferred presentation rather than as the growth rate.

2. What the payload does not know: Masimo, and a new chief executive

Two material events postdate every number in the vendor file, and one of them is one day old.

The Masimo acquisition — $9.8 billion, closed 10 June 2026

From the 10-Q filed 2026-07-21:

> "On June 10, 2026, the Company acquired Masimo by acquiring all of the outstanding shares of Masimo's common stock for a cash purchase price of approximately $9.8 billion, or $180.00 per share, net of cash acquired... Masimo develops and produces monitoring technologies, which include innovative measurements, sensors and patient monitors, serving primarily healthcare customers and is now part of the Company's Diagnostics segment. Masimo generated revenues of approximately $1.5 billion in 2025."

The purchase-price allocation, preliminary, from the same note ($M):

$9.8 billion for $1.5 billion of revenue is 6.5x sales, of which $9.80 billion — 99.2% — is goodwill and intangibles. That is the arithmetic reason the amortisation add-back keeps growing: the $4,844M of identified intangibles will be amortised over their useful lives, adding to the ~$1.9 billion annual charge management guides for 2026 and excludes from adjusted EPS.

The financing, all of it postdating the vendor's balance sheet:

• €3.0 billion of Euro-denominated notes due 2028, 2030, 2034 and 2038, completed 23 April 2026.
• CHF 2.383 billion of Swiss franc notes, private placement completed 3 June 2026 through a wholly-owned finance subsidiary, in seven series: 1.65% due 2031, 1.88% due 2033, 2.10% due 2036, 2.25% due 2038, 2.38% due 2041, 2.51% due 2046 and 2.50% due 2056.
• Commercial paper, supported by a 364-day unsecured revolving facility expiring 15 April 2027.

Coupons of 1.65% to 2.51% on thirty-year money are not available to a US-dollar issuer, and Danaher's willingness to issue in Euro and Swiss franc is a genuine, underappreciated structural advantage for a company whose model is serial acquisition. It also creates foreign-currency exposure on the principal, which the filing does not quantify here.

The pro forma disclosure, from the same note ($M): treating Masimo as if acquired at the start of the comparable prior year, second-quarter 2026 sales would have been $6,511M against the $6,265M reported, and six-month sales $12,866M against $12,203M. Masimo contributed only sixteen days to the June quarter. Pro forma diluted EPS for the June quarter was $1.27 against $1.24 reported — accretive, but not dramatically so at this stage.

The 10-Q is explicit that the accounting is unfinished: "The Company is continuing to evaluate certain pre-acquisition contingencies including property, plant and equipment, acquired intangible assets, certain acquisition-related liabilities and legal contingencies associated with the acquisition of Masimo." The filing separately discloses litigation between Masimo and Apple running in both directions, all of which "existed at the time of acquisition."

The chief-executive succession — announced 2026-08-03, one day before this dive

From the 8-K filed 2026-08-03:

> "On August 3, 2026, Danaher Corporation... announced that, effective as of October 1, 2026... the Board of Directors of the Company has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company."

> "In connection with Ms. Sawyer Montgomery's succession... effective as of the Effective Date, Rainer M. Blair will cease serving as President and CEO of the Company, and will resign as a member of the Board and from each of the Executive, Finance and Science & Technology Committees of the Board."

Blair continues as Senior Advisor through 31 December 2026 and then as a consultant until 31 March 2027. The same filing references a "Long-Term Growth Program to accelerate growth" and confirms the pending acquisition of StatLab, which remains subject to regulatory clearance.

Three observations. First, the vendor's profile.ceo field still reads "Rainer Blair" and will be wrong from 1 October. Second, the outgoing chief executive resigning from the board entirely — rather than staying as a director or becoming executive chairman — is a cleaner break than most large-cap successions, and reads as a genuine handover rather than a managed transition. Third, the timing is awkward for a valuation struck today: the new chief executive takes office nineteen days before the third-quarter print, which is the classic setting for a guidance reset, a restructuring charge, or a strategic reframing. A "Long-Term Growth Program to accelerate growth" announced in the same filing as a chief-executive change is, historically, a phrase that precedes costs.

The StatLab acquisition, from the second-quarter release: "Leica Biosystems, our anatomic pathology business, announced their intention to acquire StatLab, a leading manufacturer of products across the core histology workflow... The business has >85% recurring revenue... StatLab generated ~$250M in revenue for the full year 2025." Expected to close by the end of 2026. Roughly 1% of Danaher's revenue — the model working exactly as designed, one bolt-on at a time.

3. The four-year plateau, and what the quarters say now

Read the revenue column and the shape is unmistakable: a pandemic spike, a two-year destock, a trough, and a modest recovery that has not yet regained 2022. The FY2021-to-FY2025 decline is 16.6%; the FY2022-to-FY2024 decline, on a base already restated for the Veralto separation, is 10.4%.

And read the EPS column alongside it: $9.80 in FY2022, $5.07 in FY2025 — GAAP earnings per share have fallen 48% in three years, while share count fell 3.5%. Operating margin went from 28.3% to 20.9%. This is a franchise that has been going backwards on the reported numbers for three consecutive years, and the multiple has come down with it: the stock is 19.5% below its 52-week high and has returned −1.2% over twelve months against the S&P 500's +24.3%.

The quarterly picture, which is where the recovery shows:

Five consecutive quarters of 3-6% growth after two years of decline. The June quarter's GAAP growth of 5.5% decomposes, per management's own reconciliation, into core +3.0%, acquisitions +1.5%, currency +1.0% — so half the growth was Masimo and currency. Excluding respiratory testing, core was +4.5%.

Segment core growth in the June quarter: Biotechnology +2.5%, Life Sciences +5.5%, Diagnostics +2.0% (or +5.0% excluding respiratory testing). Management's commentary: "Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter." Mid-teens order growth in bioprocessing is the single most encouraging forward-looking datum in the file, and it is management's characterisation, half-weighted.

Note the June quarter's operating margin of 18.0%, the lowest in the table. That reflects the Masimo transaction charges the release quantifies: $34M of transaction costs and $74M of non-recurring acquisition-date fair-value adjustments to inventory, share-based payment settlements and change-in-control payments in the quarter ($108M pretax, $95M after tax). Adjusted for those, the operating margin would be near 19.7%. We name them rather than netting them, and note that they are excluded from the $1.94 adjusted EPS.

Management's FY2026 guidance, from the 2026-07-21 release — management voice, half-weighted: core revenue growth of 3.0% to 4.0%; adjusted diluted EPS of $8.45 to $8.60, raised from $8.35 to $8.55 on the earlier-than-anticipated Masimo close; amortisation of acquisition-related intangibles of approximately $1.9 billion; corporate expense approximately $360M; net interest expense approximately $310M; effective tax rate approximately 17.0%; average adjusted diluted shares approximately 709 million. Third-quarter core growth of 2.0% to 3.0%, or approximately +5.0% excluding respiratory testing.

4. The earnings-quality question a serial acquirer cannot avoid

Danaher's entire forward valuation is struck on adjusted EPS, and the largest adjustment is the amortisation of the assets it bought.

Management guides approximately $1.9 billion of acquisition-related intangible amortisation for FY2026, at an approximately 17% tax rate and roughly 709 million average diluted shares:

> $1,900M pretax × (1 − 0.17) = $1,577M after tax ÷ 709M shares = approximately $2.22 per share

Against consensus FY2026 adjusted EPS of $8.496, that is 26.1% of the number. A GAAP-equivalent figure would be near $6.28, and the multiple would be 31.0x rather than 22.9x.

The historical record corroborates the size of the gap. FY2025 consensus adjusted EPS was $7.734 against reported GAAP EPS of $5.07 — a $2.66 difference. FY2024: $7.505 adjusted against $5.33 GAAP. The gap is persistent, growing, and mechanically tied to the acquisition cadence: every deal adds intangibles, and every dollar of intangibles adds to the add-back. The Masimo transaction alone added $4,844M of identifiable intangibles.

There is a genuine argument on each side and we will not pretend otherwise.

For the add-back: the amortisation is non-cash, the acquired customer relationships and technology do not actually expire on the accounting schedule, and free cash flow — which is what pays for buybacks, dividends and the next acquisition — is unaffected. The evidence supports this: FY2025 operating cash flow was $6,416M against GAAP net income of $3,614M, an income-quality ratio of 1.66, and free cash flow was $5,260M. Cash generation is genuinely stronger than GAAP earnings suggest.

Against the add-back: Danaher's business model is acquisition. Excluding the cost of the thing you do for a living is not a normalisation, it is a redefinition. A company that spends $9.8 billion every few years to keep revenue flat has a real economic cost that GAAP amortisation approximates and adjusted EPS omits.

Our resolution. We report the forward multiple on adjusted EPS, because that is the basis every estimate in the file is struck on and mixing bases produces nonsense — but every fair value in Section 6 is sanity-checked against free cash flow and against the GAAP-equivalent multiple, and the ~31x GAAP figure is why our base sits below the street's. The honest summary: on cash, Danaher is reasonably valued; on earnings, it is not; and the difference between those two statements is $1.9 billion a year.

5. Balance sheet, cash flow and the stale-balance-sheet finding

At 2026-06-26, from the 10-Q, filing-verified ($M):

This is the finding. The vendor's bal_a block ends at 2025-12-31. Every leverage figure derivable from it — total debt $18,418M, net debt $13,803M, debt-to-equity 0.35x — predates a $9.8 billion cash acquisition and $8.1 billion of net new borrowing. A screen run on the vendor's annual balance sheet would show Danaher with 61% less net debt than it has.

And yet the vendor's km_ttm.enterpriseValueTTM of $159,102,474,295 is exactly right:

> Market cap $136,892M + net debt $22,210M = $159,102M — an exact reconciliation to the June 2026 balance sheet.

So the file is correct at the enterprise-value level and $8.4 billion wrong one layer down. That is the most dangerous shape a data defect can take, because the top-level number passes every plausibility check while the underlying block silently misstates leverage, coverage and every debt ratio derived from it. We use the 10-Q throughout.

Corrected leverage. Net debt of $22,210M against our recomputed trailing EBITDA of $7,557M (Section 8) is 2.94x — against the vendor's printed 3.452x, which is right in direction and wrong in magnitude because its EBITDA is understated. Danaher has historically operated well below 2x, so 2.94x is a genuine change in the risk profile, and management's own guidance of approximately $310M of net interest expense for FY2026 will step up materially in FY2027 as the €3.0B and CHF 2.383B issues carry a full year.

Tangible book value is negative and correctly reported. bookValuePerShareTTM of $74.551 against tangibleBookValuePerShareTTM of −$22.956 — a $97.51 difference reflecting $68,772M of goodwill and intangibles against $52,592M of equity. The vendor distinguishes them properly here, which is worth recording given how often book and tangible book have been reported as identical elsewhere in this programme. intangiblesToTotalAssetsTTM of 74.5% is the honest summary: three-quarters of Danaher's balance sheet is the accounting residue of forty years of acquisitions.

Cash flow and capital returns:

The capital-allocation pattern is legible and it is the model. No buyback in 2022-2023 while Abcam was bought; $5,979M and $3,088M of buyback in 2024-2025 while the acquisition pipeline was quiet; then $9.8 billion deployed on Masimo in June 2026. Danaher does not do both at once, and the treasury-stock movement in the first half of 2026 (+$965M) suggests buyback continued at a reduced pace alongside the deal.

The dividend is $1.44 per share, a 0.74% yield, with $878M paid in FY2025 — a 24.1% payout of GAAP earnings and 16.7% of free cash flow. This is not an income story. Total shareholder yield in FY2025 was roughly 2.9% (2.3% buyback plus 0.6% dividend), and shares outstanding fell from 706.9M to 702.9M across the first half of 2026, −0.6%.

Working capital is the one operational soft spot. Days of inventory outstanding is 114.2 and the cash conversion cycle is 108.0 days — 57.6 days of receivables plus 114.2 of inventory less 63.8 of payables. Inventory turns 3.2x. For a business with 82% recurring revenue that is a lot of working capital, and it is a structural feature of shipping reagents and instruments into regulated laboratories rather than a failure.

6. Valuation — priced in or room?

At $194.73 (market cap $136.892B, enterprise value $159.102B):

Estimate coverage is good on the near years — 16 analysts on FY2026 and FY2027 revenue, 13 on both EPS lines — and collapses beyond. FY2028 EPS rests on 5 analysts; FY2029 and FY2030 EPS each rest on ONE, and neither supports any conclusion here.

The FY2027 EPS range is the most striking single fact in the estimate block: epsLow $9.130, epsAvg $9.260, epsHigh $9.360 — a 2.5% spread across 13 analysts. For comparison, FY2028's five analysts spread from $9.151 to $10.681, a 16.7% range. A 2.5% spread means the sell-side regards Danaher's FY2027 earnings as close to arithmetically determined — which is what an 82%-recurring-revenue business with guided margins looks like — and it means the entire distribution of outcomes for the stock sits in the multiple, not the earnings. That single observation shapes every fair value below.

est.ebitdaAvg and est.ebitAvg are rejected outright. In every forward year, ebitdaAvg is exactly 31.94% of revenueAvg and ebitAvg is exactly 23.09%, to four decimals — a fixed ratio applied to the revenue line, the same fabrication signature found on other names in this batch. Corroborating defect: netIncomeAvg exceeds ebitAvg in FY2027 ($6,582.0M against $6,553.6M) and FY2028 ($7,220.0M against $6,979.4M), which is impossible. All forward valuation uses epsAvg and revenueAvg.

Peer context. The vendor peer set — Amgen, Boston Scientific, Gilead, Intuitive Surgical, McKesson, Medtronic, Pfizer, Sanofi, Stryker, Thermo Fisher — is the best-constructed peer list in this batch, and Thermo Fisher is a genuine comparable: same end markets, same instrument-and-consumables model, same serial-acquisition history. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn. What can be said is that three of the ten peers (ISRG, SYK, and DHR itself) are in this batch, and DHR is by some distance the slowest-growing of the three.

6a. What today's price assumes (the inversion)

At $194.73 — 22.9x FY2026 consensus adjusted EPS and 21.0x FY2027 — the price embeds:

• Revenue reaches $26.265B in 2026 and $28.378B in 2027. (Consensus; 16 analysts each.) Note what that is made of: Masimo contributes roughly $1.5B of annualised revenue, so roughly 70% of the $1.70B of FY2026 revenue growth is the acquisition, not the base. On core, management guides 3.0-4.0%. The nearest test is 2026-10-20: management's own third-quarter core-growth guide is 2.0-3.0%, or approximately 5.0% excluding respiratory testing.
• Adjusted EPS reaches $9.260 in 2027 and $10.180 in 2028 — 9.0% then 10.0% growth on a 3-4% core-growth revenue base. (Consensus.) That requires roughly 500-600 basis points of annual EPS growth from margin, buyback and acquisition beyond what the top line delivers, in a year when net interest expense steps up on the Masimo financing.
• The ~$1.9 billion of annual acquisition-intangible amortisation continues to be treated as excludable. (Our derivation from management's guidance.) This is the most fragile assumption in the price — not because the accounting will change, but because the market's willingness to pay 21x an adjusted number that excludes 26% of itself is a convention, and conventions re-rate faster than earnings do. On a GAAP-equivalent basis the multiple is 31x for a 3-4% grower.
• Net debt of $22.2 billion comes down without impairing capital deployment. (Our number, from the 10-Q.) At 2.94x recomputed EBITDA, Danaher has less acquisition capacity than at any point in recent years, and acquisition capacity is what the knowledge base's four claims all admire.
• The market keeps paying roughly 21x or better on the forward year. (Our number.) At 17x FY2027E the stock is $157; at 25x it is $232. With the earnings estimate spread at 2.5%, the multiple is essentially the whole variance.

6b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: adjusted EPS growth (+9.0%, from FY2026E $8.496 to FY2027E $9.260) + multiple drift (mild COMPRESSION, from 22.9x on the forward year to roughly 22x on the then-forward year, about −4%) + shareholder yield (+2.9%) ≈ +5% to +9%.

Our base assumes mild compression rather than expansion, for two reasons that are not the same. The first is growth: consensus EPS growth is 9.0% then 10.0%, and 21-23x is already a full multiple for that rate in healthcare tools. The second is composition: an increasing share of the growth is acquired rather than organic, and acquired growth carries a lower multiple because it consumes balance-sheet capacity. We do not assume a de-rating to a punitive level — Danaher's franchise quality does not warrant it — only that the market does not pay more for a slower-growing, more-levered version of the same company.

Almost all of the expected return is earnings growth plus shareholder yield. If the multiple held at 22.9x on FY2027E the price would be $212 (+8.9%). If it compressed to 18x the price would be $167 (−14.3%). The bull case at $255 requires the market to pay 27.2x — a level Danaher has carried before, in 2021, when it was growing 32%. That is the honest statement of what the bull case needs.

6c. Variant perception (where we differ, what would surprise)

• We differ from the street by 7.5%, downward — $205 against $221.58 — and the difference is entirely the earnings basis. Thirty of 43 analysts are at buy or better. Our number is lower because we sanity-check the 21x adjusted multiple against a ~31x GAAP-equivalent multiple for a business guiding 3-4% core growth, and the second number does not support the first. That is a stated disagreement about a convention, not about the business, and we hold it loosely.
• We differ from the vendor data on leverage, materially and in the direction that matters. Every screen built on the vendor's annual balance sheet shows Danaher with $13.8 billion of net debt; the correct figure at 2026-06-26 is $22.2 billion. That moves net-debt-to-EBITDA from roughly 1.8x to 2.94x and it is the difference between a company with acquisition firepower and one that has just spent it. The vendor's enterprise value is nonetheless exactly right, which is precisely why the error is dangerous.
• We think the succession is being under-weighted relative to the acquisition. The market has had eight weeks to price Masimo and one day to price a chief-executive change. A new chief executive taking office nineteen days before a quarterly report, with a "Long-Term Growth Program" already announced in the same 8-K, is the standard setting for a reset. Watchable event: the 2026-10-20 print and whether the $8.45-8.60 FY2026 adjusted EPS guidance survives it. Consensus at $8.496 already sits at the bottom of that range, which suggests the sell-side is not fully crediting the raise — and gives the new chief executive room to reaffirm rather than cut.
• Positive surprise that would force a re-rate: bioprocessing revenue converting the mid-teens order growth management described, with Biotechnology core growth moving above 5%; or Masimo proving more accretive than the pro forma implies; or the new chief executive setting out a credible path back to mid-single-digit organic growth with numbers attached. Any of those turns a 3-4% grower into a 5-6% grower, and 21x becomes 24-25x.
• Negative surprise that would break the thesis: third-quarter core growth below 2.0%, i.e. missing management's own floor; a restructuring charge or guidance reset accompanying the leadership change; an adverse development in the Masimo-Apple litigation the 10-Q discloses; a goodwill or intangible impairment against the $68.8 billion carried on the balance sheet; or China, at $2,631M and falling three years running, deteriorating further.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $9.260, low $9.130, high $9.360, 13 analysts), cross-checked against FY2026E of $8.496 and against free cash flow. Because the estimate spread is only 2.5%, the anchors are deliberately driven by multiple rather than by estimate dispersion — that is where the actual uncertainty lives.

• Bear ~$155 — 17.0x the FY2027 consensus LOW of $9.130. Cross-check: 18.2x FY2026E; roughly 25x a GAAP-equivalent FY2027 figure; 4.4% below the 52-week low of $161.91. The scenario: the plateau persists, core growth settles at 2-3%, the Masimo integration disappoints, net interest steps up, the new chief executive resets guidance, and the market applies a mature-industrial multiple to a 3% grower. −20.4%.
• Base ~$205 — 22.1x the FY2027 consensus MEAN of $9.260. Cross-check: 24.1x FY2026E; 20.1x FY2028E; enterprise value of $166.3B on FY2027E revenue of $28.378B is 5.9x sales; roughly 32.6x our GAAP-equivalent FY2026 figure of $6.28. Sensitivity, stated openly: 20x gives $185 — 4.9% BELOW spot — and 24x gives $222, essentially the street. The whole answer lives in a 20-24x band on one estimate row. The scenario: consensus lands, the recovery continues at a modest pace, leverage comes down gradually, and the multiple holds roughly where it is. +5.3%.
• Bull ~$255 — 27.2x the FY2027 consensus HIGH of $9.360. Cross-check: 30.0x FY2026E; 5.4% above the 52-week high of $242.05. The scenario: bioprocessing inflects to mid-single-digit-plus, Masimo outperforms, the new chief executive articulates a growth agenda the market believes, and Danaher re-rates toward the multiple it carried when it was a growth company. +31.0%.

Base is 5.3% above spot; asymmetry roughly 1.52:1 to the upside (20.4% down, 31.0% up). That ratio is unremarkable and the base case is thin. What keeps this a Watch rather than a Hold is franchise quality and the possibility that the leadership change produces a genuinely lower entry.

7. Knowledge base — four hits, three about a business model, none about this stock

Raw hits: 4. Entity matches: 3. Text-only: 1. Used as name-level conviction: 0. Used as supporting colour: 3. Discarded: 1.

The sweep ran entity terms DHR, Danaher, Danaher Corporation, Cepheid, Cytiva, Masimo and Beckman Coulter, plus a free-text sweep on danaher, bioprocessing and Danaher Business System, across all 51,928 distilled claims. No homograph collisions occurred — "Danaher" is a clean token, unlike the short tickers elsewhere in this batch.

The three entity-matched claims, verbatim:

> 2024-10-14 · bullish · conviction 70 · horizon: principle · entities: Danaher, Constellation Software · channel: business_breakdowns · no named speaker · skill 1.0

> "Ametek belongs with Danaher and Constellation as a proven decentralized niche-acquirer compounder model worth studying."

> 2025-08-02 · bullish · conviction 70 · horizon: principle · entities: Danaher, TransDigm, Constellation Software, Berkshire Hathaway · channel: cognitive_revolution · no named speaker · skill 1.0

> "Compounders that buy companies, improve them, and redeploy free cash flow into more acquisitions have been outstanding public-market performers and hedge-fund favorites."

> 2026-04-17 · bullish · conviction 70 · horizon: thesis · entities: Apple, Microsoft, Western Digital, Nvidia, Danaher · channel: compound_and_friends · no named speaker · skill 1.0

> "These are examples of 'life cycle change' companies figuring out how to grow again after saturating their original markets."

And the discard:

> 2023-05-21 · entity: Diploma · channel: business_breakdowns — "Extreme decentralization (30-40 autonomous businesses with own CEOs) drives agile, entrepreneurial culture — key to success, like Berkshire, Constellation, Danaher." This claim is about Diploma. Danaher appears only as an analogy inside the thesis text and the claim is not entity-tagged to it. Discarded from the lane.

What this lane is, stated without inflation.

Not one of the three is a claim about Danaher. Each uses the company as a member of a set:

• The 2024-10-14 claim is a claim about Ametek, using Danaher as a reference point for what a good serial acquirer looks like.
• The 2025-08-02 claim is a claim about the serial-acquirer category, with Danaher as one of four illustrations.
• The 2026-04-17 claim is a basket observation about companies re-accelerating after market saturation, in which Danaher appears alongside four technology names it has nothing else in common with.

All four hits carry speaker: null and are attributed only to a channel — the weakest form of sourcing the 4-lane attribution policy admits, and precisely the failure mode that policy exists to catch. Three of the four are horizon principle, meaning they are statements about business models rather than about securities at prices.

No claim in the lane mentions Masimo, bioprocessing, the Veralto separation, the four-year revenue plateau, or the chief-executive succession. The most recent is 2026-04-17, which predates the Masimo close, the second-quarter print and the leadership change.

No concentration sensitivity test is meaningful here — four claims across three channels is not a lane with a concentration problem, it is a lane with an existence problem.

Conclusion, stated as a finding. The Synthos knowledge base admires the Danaher model and has no view on Danaher the security. The admiration is a genuine, independent corroboration of the qualitative case in Section 1 — 82% recurring revenue, 58.5% gross margin and a forty-year acquisition record are exactly what those claims describe — and it is worth precisely nothing as a valuation input. Breadth 3, net conviction positive-negligible, and the thinness is a direct input to the Watch verdict.

8. Data integrity — what we rejected and why

Nine findings. Danaher's file has one severe defect (a balance sheet stale across a $9.8 billion acquisition), one severe omission (40.6% of revenue missing from the geographic block), and two fields that are simply out of date — against a correctly computed enterprise value and a correctly distinguished tangible book value.

1. bal_a is stale across the largest transaction in the file — REJECTED and rebuilt from the 10-Q. The vendor's most recent balance sheet is 2025-12-31, showing total debt of $18,418M and net debt of $13,803M. Danaher closed the $9.8 billion Masimo acquisition on 10 June 2026, financed with €3.0B of Euro notes (April), CHF 2.383B of Swiss franc notes (3 June), commercial paper and a 364-day facility. The 10-Q filed 2026-07-21 shows total debt of $26,558M ($1,411M current + $25,147M long-term) and cash of $4,348M — net debt of $22,210M, 61% higher, an $8,407M gap. Goodwill rose $4,263M and intangibles $3,541M in the same period. The vendor reports net debt of $13,803M; the filing shows $22,210M; we use $22,210M, and every leverage figure in this dive is computed on it.

2. The same file's enterpriseValueTTM is EXACTLY correct — which is what makes finding 1 dangerous. km_ttm.enterpriseValueTTM of $159,102,474,295 reconciles precisely to market cap $136,892M plus net debt $22,210M from the June 2026 balance sheet. So the vendor's enterprise value is built on data the vendor's own balance-sheet block does not contain. A reader checking the enterprise value would find it sound and conclude the file is current; a reader computing leverage from bal_a would understate net debt by $8.4 billion. Both operations are performed on the same file and only one of them is right.

3. seg_geo for FY2025 omits the United States — 40.6% of revenue missing. The vendor reports two lines for FY2025: "Other developed markets" $11,956M and "CHINA" $2,631M, summing to $14,587M against reported revenue of $24,568M. These are taken from the 10-K's country table (United States $9,981M, China $2,631M, All other $11,956M), with "All other" mislabelled as "Other developed markets" and the United States line dropped entirely. The FY2024 entry is complete but carries the same mislabelling (its "North America" line of $9,927M is the United States figure). No geographic figure in this dive comes from the vendor block; all come from the 10-K's Note 5 regional table and its country table.

4. seg_prod is the recurring/nonrecurring revenue split, not a segment table — used, relabelled. The two lines are "Revenue from Contract with Customer, Measurement, Recurring" ($20,127M) and "...Nonrecurring" ($4,441M), summing exactly to FY2025 revenue. The figures are correct and genuinely useful; they are simply not segments. Danaher's three reportable segments — Biotechnology $7,293M, Life Sciences $7,334M, Diagnostics $9,941M — appear nowhere in the payload and are taken from the 10-K's Note 5. Note also that the block's older entries (2012-2017) carry the pre-Veralto, pre-Fortive segment vocabulary (Dental, Test & Measurement, Industrial Technologies) and are not comparable with anything current.

5. profile.ceo is superseded and profile.description is two segment structures out of date. The vendor names Rainer Blair as chief executive; the 8-K filed 2026-08-03, one day before this dive, appoints Julie Sawyer Montgomery as President and Chief Executive Officer effective 1 October 2026, with Blair resigning from the board. The description states Danaher "is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions" — Environmental & Applied Solutions was separated as Veralto in October 2023 and the current third segment is Biotechnology.

6. Trailing EBITDA is internally contradictory — REJECTED and recomputed. ratios_ttm.ebitdaMarginTTM of 25.626% implies trailing EBITDA of $6,434M, which against trailing operating income of $5,127M implies depreciation and amortisation of only $1,307M. But FY2025 cash-flow D&A was $2,447M, and the vendor's own capexToDepreciationTTM of 0.4811 against trailing capex of $1,169M independently implies $2,430M. We compute EBITDA as operating income $5,127M + D&A $2,430M = $7,557M (30.1% margin), moving evToEBITDATTM from 24.73x to ~21.1x and netDebtToEBITDATTM from 3.452x to 2.94x. Caveat stated openly: roughly $1.9 billion of that D&A is acquisition-intangible amortisation, so this EBITDA figure flatters cash generation for exactly the reason discussed in Section 4.

7. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED in full. In every forward year, ebitdaAvg is exactly 31.94% of revenueAvg and ebitAvg is exactly 23.09%, to four decimals. Corroborating defect: netIncomeAvg exceeds ebitAvg in FY2027 ($6,582.0M against $6,553.6M) and FY2028 ($7,220.0M against $6,979.4M) — impossible. All forward valuation uses epsAvg and revenueAvg.

8. The FY2029 and FY2030 estimate rows rest on ONE analyst each — EXCLUDED. numAnalystsEps is 1 for both 2029 ($11.388) and 2030 ($12.48), against 13 for 2026 and 2027. Neither supports any conclusion. FY2028 EPS rests on 5 analysts with a $9.151-$10.681 range and is shown for context only.

9. epsdiluted is null in every row of inc_a and inc_q — worked around. The vendor supplies eps and weightedAverageShsOutDil but no diluted EPS. All per-share figures in this dive are computed and labelled, and cross-checked against the 10-Q where possible.

Not defects, correctly reported and independently confirmed: the enterprise value (finding 2); the share count (10-Q cover 702.9M outstanding at 2026-06-26 against 703.0M implied by market cap ÷ price); bookValuePerShareTTM of $74.551 correctly distinct from tangibleBookValuePerShareTTM of −$22.956, a genuinely negative tangible book properly reported; the FY2025, FY2024 and FY2023 revenue, gross profit, operating income and net income lines, all matching the 10-K; the recurring/nonrecurring split; incomeQualityTTM of 1.657, correctly reflecting $6,416M of operating cash flow against $3,614M of net income; and intangiblesToTotalAssetsTTM of 74.5%.

Vendor composite rating — accepted with one caveat. The rating block gives B+ / 3 overall, with 2 out of 5 on debt-to-equity and 2 on price-to-earnings. The debt-to-equity sub-score is computed on the stale balance sheet and therefore understates leverage — on the correct figures it would be worse. The rest of the composite is unobjectionable and we do not reject it, but we note that it flatters the balance sheet for the reason in finding 1.

Non-equity tripwire — checked and passed. DHR is common stock, $0.01 par value, NYSE-listed, per the 10-Q balance sheet. Price of $194.73 is not par-like; beta is 0.823; the dividend is variable; volume was 4.91M shares (~$956M of turnover); the 52-week band of $161.91 to $242.05 is a 49% range. This is common equity.

9. Technicals

• Price $194.73. −19.5% from the 52-week high of $242.05; +20.3% above the 52-week low of $161.91. Position within the annual range: 41st percentile.
• Moving averages, split and unusually tight: +3.2% above a 50-day average of $188.63; −4.4% below a 200-day average of $203.61. The two averages are only 7.9% apart, which is a compressed, range-bound configuration rather than a trend in either direction.
• RSI 45.1 — neutral. MACD +1.71 — positive, and the only positive MACD reading among the large-cap technology and healthcare names in this batch. A stock that has stopped going down.
• Maximum drawdown from peak over the trailing year: −33.9%, against a current drawdown of −19.5% — so the stock has recovered roughly 14 points from its worst point.
• Relative performance, and the shape matters: 3-month +11.9% against SPY +7.6% and QQQ +7.7% — outperforming; 6-month −12.8% against SPY +11.1% and QQQ +15.7% — badly lagging; 12-month −1.2% against SPY +24.3% and QQQ +30.8% — a 25.5-point deficit. The underperformance is a year old and the most recent quarter has reversed it. That is what a bottoming process looks like, though it is equally what a bear-market rally looks like and one quarter does not distinguish them.
• Sentiment: 1 strong buy, 29 buy, 12 hold, 1 sell across 43 analysts; consensus target $221.58 (+13.8%), median $225, high $249 (+27.9%), low $195 — essentially at spot. A low target that equals the current price is unusual and means no analyst in the file sees material downside — which, given the earnings-basis question in Section 4, is itself worth noting as a possible blind spot rather than a comfort.

Today's move and what it does to the entry

DHR closed 2026-08-04 at $194.73, down 1.40% or $2.77 from $197.50. It opened at $197.93, traded $192.99 to $200.36, and closed near the bottom of the range on 4.91M shares. On a day when most of this batch rose sharply, Danaher fell — and the only company-specific news is the 8-K filed the previous day announcing the chief-executive succession. A 1.4% decline on a leadership-change announcement is a mild negative reaction, not a repudiation, and it is consistent with a market that regards the incoming chief executive as an unknown rather than a problem.

The honest read: there is nothing in this chart to act on in either direction. The stock sits between its two moving averages, RSI is 45, and MACD has just turned positive. The valuation, not the chart, is why this is a Watch.

What would change it:

• A price near $170-175 — roughly 18-19x FY2027E, and near the 52-week low of $161.91 — which would put our base $205 at an 17-21% premium. That is 10-13% below today's close. A guidance reset accompanying the October leadership transition is the single most plausible route there.
• Or the 2026-10-20 print showing Biotechnology core growth above 5% with the FY2026 adjusted EPS guidance of $8.45-8.60 reaffirmed by the new chief executive. That converts a 3-4% grower into a mid-single-digit grower and makes 22-24x defensible.

10. Insiders — eight transactions, all mechanical, and nothing to read

The reading is short because there is nothing here. Two directors exercised identical option tranches of 3,298 shares at $71.88 on the same day and settled the tax liability by having 1,181 shares withheld by the issuer at $200.79 — a net-settled exercise, executed identically by both, which is the signature of a scheduled expiry rather than a decision. The chief accounting officer had 60 shares withheld. One director received a routine 680-share grant in May.

Zero open-market purchases. Zero open-market sales. Every disposition in the file is F-InKind withholding, which is not a sale — the company retains the shares and remits cash to the tax authority. This is a neutral signal and is reported as neutral.

Two things worth one line each. The withholding priced at $200.79, 3.1% above today's close — so the insider transactions in this file were struck near current levels, unlike several other names in this batch. And there is no transaction by the chief executive, the chief financial officer, or the incoming chief executive anywhere in the file — which, three weeks before a succession announcement, is exactly what compliance would require and therefore carries no information at all.

11. Verdict, kill-criteria and flip conditions

Watch.

What is genuinely excellent: 81.9% of revenue recurring, at $20,127M and growing 7.7% over two years while non-recurring fell; a 58.5% gross margin held within a 56-61% band across six years spanning a pandemic boom and a two-year destock; $5,260M of free cash flow on $24,568M of revenue, a 21.4% conversion, with an income-quality ratio of 1.66; three segments serving pharmaceutical, biotechnology and clinical-laboratory customers whose demand does not disappear; a forty-year serial-acquisition record that the knowledge base names alongside Berkshire Hathaway and Constellation Software; access to thirty-year money at 2.50% in Swiss francs; and $3,088M of stock repurchased in FY2025 against a shrinking share count.

What we are declining to pay for: revenue that is 16.6% lower than FY2021 and 10.4% below the restated FY2022 base; GAAP earnings per share that have fallen from $9.80 to $5.07 in three years; management guidance of 3.0-4.0% core growth; 21.0x FY2027 consensus adjusted EPS, where "adjusted" excludes approximately $1.9 billion — about $2.22 per share after tax, 26% of the number — of amortisation on the very acquisitions that constitute the business model, making the GAAP-equivalent multiple nearer 31x; net debt that went from $13.8 billion to $22.2 billion, roughly 2.94x recomputed EBITDA, in a single quarter; a chief-executive transition effective in eight weeks with a "Long-Term Growth Program" already announced; a base fair value of $205 that is 5.3% above spot and 7.5% below the street's $221.58; and a knowledge-base lane of three claims, none of which is about this company.

The distinction that matters. Danaher is not a broken business and we are not calling for one. It is a very good business at a price that requires it to be a growing one, at a moment when it has been flat for four years, has just spent $9.8 billion to add 6% to revenue, and is changing its chief executive. In the Synthos frame, a name where our fair value sits 5% above the price and below the street's, with an empty conviction lane and a leadership transition inside the horizon, is a Watch by construction. The quality argues for owning it eventually; nothing argues for owning it today.

Pre-registered KILL criteria — what would take this to Avoid:

• Third-quarter core sales growth below 2.0%, i.e. missing the floor of management's own guidance, or a cut to the FY2026 adjusted EPS range of $8.45-8.60.
• Biotechnology core growth turning negative again after the mid-teens order growth management described — that would say the bioprocessing recovery has stalled a second time.
• A goodwill or intangible impairment against the $68.8 billion carried on the balance sheet. At 74.5% of total assets, an impairment here is not a footnote.
• Net debt failing to fall below roughly 2.5x EBITDA within twelve months, which would say the acquisition engine — the whole basis of the knowledge base's admiration — is out of fuel.
• An adverse resolution of the Masimo-Apple litigation disclosed in the 10-Q, or a material adverse adjustment to the still-open purchase-price allocation.
• China revenue falling below roughly $2.3B, extending a three-year decline from $3,143M.

Pre-registered FLIP conditions — what would take this to Buy — Tactical:

• A price in the $170-175 band with no fundamental deterioration — roughly 18-19x FY2027E — putting the base case at +17% to +21%. This is the single most likely path to a Buy, and a guidance reset accompanying the 1 October leadership change is the most plausible route there.
• The 2026-10-20 print showing Biotechnology core growth above 5% with FY2026 guidance reaffirmed, which converts a 3-4% grower into a mid-single-digit one and makes today's multiple defensible.
• A credible, quantified organic-growth plan from the incoming chief executive — the "Long-Term Growth Program" with numbers attached rather than a phrase in an 8-K.
• Net debt back below 2.0x EBITDA with the buyback resumed at the FY2024 pace, which would restore the capital-deployment optionality that is half the investment case.
• Genuine name-level knowledge-base conviction appearing — a claim about Danaher rather than about the category containing Danaher. At present there is none, and that alone is worth roughly one tier.

Where DHR fits in the Synthos Framework Portfolio. The life-sciences-tools sleeve, at 0% today with a 1.5-2.5% target on a fill in the $170-175 band or a confirming October print. On batch overlap: ISRG, SYK and DHR are all in this batch and all in the vendor's own peer set for each other, but they are not the same exposure — DHR sells consumables into laboratories, ISRG and SYK sell capital equipment and implants into operating theatres. Within healthcare, DHR is the slowest-growing and the cheapest of the three on forward earnings, and the one whose reported multiple most depends on an adjustment convention. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $194.73.

Single biggest risk: the plateau does not break. Revenue is $24,568M against $29,453M four years ago, and the FY2022-to-FY2024 contraction of 10.4% was on a base already restated for the Veralto separation, so it is a genuine like-for-like decline. At 21.0x forward adjusted earnings — and roughly 31x on a GAAP-equivalent basis — the price assumes a company that grows mid-single digits and compounds earnings at 9-10%. Management guides 3.0-4.0% core, and roughly 70% of the FY2026 revenue increase in the consensus is Masimo arriving rather than the base growing. If core growth settles at 2-3% and the market decides that a serial acquirer's amortisation is a real cost after all, the multiple has two independent reasons to compress at once. That is the $155 bear case, and it requires no crisis — only for the last four years to continue.

Provenance & disclosures

• Traceability: 3 tagged knowledge-base claims name Danaher out of 51,928 distilled claims (raw hits 4, entity matches 3, text-only 1, used as name-level conviction 0, used as supporting colour 3, discarded 1; breadth 3, net conviction positive-negligible). Sources: business_breakdowns (2024-10-14, conviction 70 — Ametek grouped with Danaher and Constellation Software as decentralised niche-acquirer compounders), cognitive_revolution (2025-08-02, conviction 70 — serial-acquirer compounders named alongside TransDigm, Constellation Software and Berkshire Hathaway) and compound_and_friends (2026-04-17, conviction 70 — a 'life cycle change' basket with Apple, Microsoft, Western Digital and Nvidia). All three use Danaher as an EXEMPLAR of a business model rather than as a subject; none is name-level conviction; three of the four hits are horizon principle. All four carry speaker: null and are attributed only to a channel — the weakest sourcing the 4-lane policy admits. No claim carries a management speaker_role, so the half-weight management discount does not apply. One discard: a 2023-05-21 business_breakdowns claim about Diploma's decentralisation which mentions Danaher only as an analogy in the thesis text and is not entity-tagged to it. No homograph collisions — 'Danaher' is a clean token. No concentration sensitivity test is reportable: four claims across three channels is not a concentration problem, it is an absence. The most recent claim (2026-04-17) predates the Masimo close, the second-quarter print and the chief-executive succession. All quotes are verbatim from the stored claim text.
• Data as-of: fundamentals — balance sheet and acquisition accounting through 2026-06-26, filing-verified from the 10-Q filed 2026-07-21; annual figures for FY2025, FY2024 and FY2023 from the 10-K filed 2026-02-24; second-quarter results, guidance and segment core-growth detail from the 8-K filed 2026-07-21, which carries the full earnings release; chief-executive succession from the 8-K filed 2026-08-03, one day before this dive · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873599 = 2026-08-04T19:59:59Z ($194.73, −1.40%; 50-DMA $188.63; 200-DMA $203.61; RSI 45.1; MACD +1.71) · knowledge-base claims 2026-08-04. Danaher's fiscal year ends 31 December; quarters end on the Friday nearest quarter-end (Q2 2026 ended 2026-06-26). All figures come from the Synthos vendor data file for DHR or from the SEC filings in the DHR archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents: 10-K filed 2026-02-24 (fiscal 2025); 10-Q filed 2026-04-21 (March 2026 quarter); 10-Q filed 2026-07-21 (June 2026 quarter — the source of the Masimo purchase accounting, the corrected balance sheet and the debt detail); 8-K filed 2026-06-03 (the CHF 2.383B private placement in seven series); 8-K filed 2026-07-21 (full second-quarter earnings release with FY2026 guidance and segment core growth); 8-K filed 2026-08-03 (chief-executive succession, Long-Term Growth Program, pending StatLab acquisition). All carry preserved [TABLE] statement data.
• Where the filings contradicted or corrected the vendor (detailed in Section 8): the balance sheet, which is the headline finding — the vendor's most recent is 2025-12-31 showing net debt of $13,803M, while the 10-Q at 2026-06-26 shows total debt of $26,558M against cash of $4,348M for net debt of $22,210M, a 61% / $8,407M gap created by the $9.8 billion Masimo acquisition of 10 June 2026 and its €3.0B / CHF 2.383B financing, none of which appears anywhere in bal_a or cf_a; seg_geo for FY2025, which omits the United States line of $9,981M (40.6% of revenue) and mislabels the "All other" line, summing to $14,587M against reported revenue of $24,568M; seg_prod, which is the recurring/nonrecurring split rather than a segment table, with the three actual segments (Biotechnology, Life Sciences, Diagnostics) absent from the payload entirely; profile.ceo, naming Rainer Blair against the 2026-08-03 appointment of Julie Sawyer Montgomery effective 2026-10-01; profile.description, describing an Environmental & Applied Solutions segment separated as Veralto in October 2023; trailing EBITDA, recomputed from the vendor's internally contradictory $6,434M to $7,557M (operating income $5,127M plus D&A of $2,430M, which the vendor's own capexToDepreciationTTM independently implies), moving EV/EBITDA from 24.73x to ~21.1x and net-debt/EBITDA from 3.452x to 2.94x; and est.ebitdaAvg/ebitAvg, rejected in full for a fixed-ratio signature (exactly 31.94% and 23.09% of revenue in every forward year) with netIncomeAvg exceeding ebitAvg in two years. Where vendor and filing AGREED — recorded because the contrast with finding 1 is the whole lesson: enterpriseValueTTM of $159,102,474,295 reconciles exactly to market cap plus the JUNE 2026 net debt, so the vendor's enterprise value is built on data its own balance-sheet block does not contain; the share count (10-Q 702.9M outstanding at 2026-06-26 against 703.0M implied); bookValuePerShareTTM of $74.551 correctly distinct from tangibleBookValuePerShareTTM of −$22.956; and the FY2025, FY2024 and FY2023 income-statement lines.
• Basis note: analyst estimates and the company's guidance are on adjusted (non-GAAP) diluted EPS, which excludes acquisition-related intangible amortisation (guided at approximately $1.9 billion for FY2026, roughly $2.22 per share after tax at the guided 17% rate on approximately 709M average diluted shares), restructuring, fair-value adjustments to acquired inventory, transaction costs and discrete tax items. Reported diluted EPS is GAAP. The gap is large and growing: FY2025 adjusted consensus $7.734 against GAAP $5.07; FY2024 $7.505 against $5.33. Forward multiples in this dive use consensus adjusted EPS (22.9x FY2026E, 21.0x FY2027E); the trailing multiple is shown on GAAP (34.3x); and a GAAP-equivalent forward figure of roughly 31x is stated explicitly wherever the adjusted multiple appears. Section 4 sets out the argument on both sides. This choice materially affects the verdict and is disclosed for that reason.
• Estimate coverage: 16 analysts on FY2026 and FY2027 revenue, 13 on both EPS lines — the anchor for all three fair values, with an FY2027 range of $9.130 to $9.360, a 2.5% spread, meaning the sell-side sees essentially no earnings uncertainty and the entire outcome distribution sits in the multiple. FY2028 EPS rests on 5 analysts ($9.151-$10.681); FY2029 and FY2030 EPS each rest on ONE analyst and are excluded from every conclusion.
• Peer note: the vendor peer set — Amgen, Boston Scientific, Gilead, Intuitive Surgical, McKesson, Medtronic, Pfizer, Sanofi, Stryker, Thermo Fisher — is the best-constructed peer list in this batch, and Thermo Fisher is a genuine comparable in end market, business model and acquisition history. No peer multiples are supplied in the file, so no peer-multiple comparison is drawn. Three of the ten (DHR, ISRG, SYK) are in this batch.
• Fair-value caveat: the $155 / $205 / $255 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 17.0x the low of $9.130, 22.1x the mean of $9.260, and 27.2x the high of $9.360. Because that distribution spans only 2.5%, the anchors are driven deliberately by multiple rather than by estimate dispersion, which is where the real uncertainty lives. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 20x gives $185, BELOW spot; 24x gives $222, essentially the street.
• Management-voice note: the FY2026 guidance (core revenue growth 3.0-4.0%, adjusted diluted EPS $8.45-8.60, amortisation ~$1.9B, net interest ~$310M, tax rate ~17.0%, average diluted shares ~709M), the third-quarter core-growth guide (2.0-3.0% total, ~+5.0% excluding respiratory testing), the statement that bioprocessing orders "grew mid-teens in the quarter", the expectation of exiting 2026 at a mid-single-digit core rate, and the "Long-Term Growth Program to accelerate growth" are all management's own claims and are half-weighted throughout per house rule, and labelled wherever quoted.
• Timing: second-quarter 2026 results were released 2026-07-21, fourteen days before this dive; the chief-executive succession was announced 2026-08-03, ONE DAY before it. The next print is 2026-10-20, 77 days away, and the leadership transition takes effect 2026-10-01, nineteen days earlier — a sequence that is an explicit input to the Watch verdict. 2026-08-04 was a broad technology up-day across this batch; Danaher fell 1.40%, the only decline among the names covered here, with the succession 8-K as the only company-specific news.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.